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Context: An association between germline aryl hydrocarbon recep-
tor-interacting protein (AIP) gene mutations and pituitary adenomas
was recently shown.
Objective: The objective of the study was to assess the frequency of
AIP gene mutations in a large cohort of patients with familial isolated
pituitary adenoma (FIPA).
Design: This was a multicenter, international, collaborative study.
Setting:The study was conducted in 34 university endocrinology and
genetics departments in nine countries.
Patients: Affected members from each FIPA family were studied.
Relatives of patients with AIP mutations underwent AIP sequence
analysis.
MainOutcomeMeasures: Presence/absence and description of AIP
gene mutations were the main outcome measures.
Intervention: There was no intervention.
Results: Seventy-three FIPA families were identified, with 156 pa-
tients with pituitary adenomas; the FIPA cohort was evenly divided
between families with homogeneous and heterogeneous tumor ex-
pression. Eleven FIPA families had 10 germline AIP mutations. Nine
mutations, R16H, G47_R54del, Q142X, E174frameshift, Q217X,
Q239X, K241E, R271W, and Q285frameshift, have not been described
previously. Tumors were significantly larger (P  0.0005) and diag-
nosed at a younger age (P  0.0006) in AIP mutation-positive vs.
mutation-negative subjects. Somatotropinomas predominated among
FIPA families with AIP mutations, but mixed GH/prolactin-secreting
tumors, prolactinomas, and nonsecreting adenomas were also noted.
Approximately 85% of the FIPA cohort and 50% of those with familial
somatotropinomas were negative for AIP mutations.
Conclusions: AIP mutations, of which nine new mutations have been
described here, occur in approximately 15% of FIPA families. Although
pituitary tumors occurring in association with AIP mutations are pre-
dominantly somatotropinomas, other tumor types are also seen. Further
study of the impact of AIP mutations on protein expression and activity
is necessary to elucidate their role in pituitary tumorigenesis in FIPA.
(J Clin Endocrinol Metab 92: 1891–1896, 2007)
PITUITARY ADENOMAS OCCUR relatively frequentlybased on autopsy and radiological series, while recent
clinical data suggest aprevalenceof approximately one caseper
thousand of the population (1, 2). Tumorigenesis of sporadic
adenomas has been attributed to genetic and molecular abnor-
malities involving gsp, pituitary tumor transforming gene, and
a pituitary derived truncated form of fibroblast growth factor
receptor-4 (3–6). Pituitary adenomas due to hereditary causes
are uncommon and can occur in the setting of multiple endo-
crine neoplasia-1 (MEN1) and Carney complex (CNC), due to
mutations in the genes encoding menin (MEN1) and the R1a
regulatory subunit of protein kinase A (PRKAR1A), respec-
tively (7–9). However,MEN1 and PRKAR1Amutations are an
infrequent cause of sporadic pituitary tumors (10). Interest has
also focused on isolated familial somatotropinomas (IFSs),
whichwere thought tobe linked toa locus close to that ofMEN1
onchromosome11q13 (11).Vierimaa et al. (12) recently reported
that inactivating mutations of the gene encoding aryl hydro-
carbon receptor interacting protein (AIP) on chromosome
11q13.3 occurred in patients with pituitary tumors (mainly ac-
romegaly) in the familial and sporadic settings. Recently, we
described familial isolated pituitary adenomas (FIPA) in 64
families with two or more pituitary tumors in patients without
MEN1 orPRKAR1Amutations or clinical/biochemical features
ofMEN1/CNC that included a broader tumor phenotype than
IFS (13). To address the potential role of AIP mutations in
families having the FIPA phenotype, we undertook a genetic
screening program involving both the original FIPA cohort and
newly identified families.
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Patients and Methods
This was an international study of AIP mutations in families having
the FIPA phenotype performed across nine countries (Belgium, France,
Italy, United States, Spain, Brazil, Argentina, The Netherlands, and
Czech Republic). The clinical characteristics of the original FIPA cohort,
involving 64 families (138 affected individuals), have been described
previously (13). Clinical, biochemical, and genetic studies excluded
MEN1 and CNC in all cases. Families with affected individuals that had
the same tumor type throughout were termed “homogeneous,” and the
remaining families had different or “heterogeneous” pituitary tumors
among affected subjects.
From the original FIPA cohort, 51 families took part in the current study
of AIPmutations. In addition, 22 new, previously undescribed FIPA fam-
ilies without MEN1 or CNC were identified and included in the study.
Relevant data on demographics and clinical characteristics were collected
for each affectedmember of each family, including age at diagnosis, tumor
size, and if available, pituitary hormone immunohistochemistry. Age at
diagnosis and mean maximum tumor diameter in the FIPA group overall
and for AIP mutation-affected subjects only were calculated as means,
medians, 95% confidence intervals, and sd. In families in which amutation
in AIP was noted, genetic analysis for this mutation was offered in other
affected and unaffected family members; clinical, hormonal, and radiolog-
ical (magnetic resonance imaging) assessment of individuals that were
positive for anAIPmutationwas also offered. The studywas conducted in
accordancewith the guidelines inTheDeclaration ofHelsinki, approvedby
the Ethics Committee of the University of Lie`ge, and all subjects provided
informed written consent in their own language for the genetic analyses
performed during the study.
Statistical analyses
Statistical analyseswere performed usingGraphPad Instat forMacin-
tosh (GraphPad Software, San Diego, CA). The Mann-Whitney test for
univariate analyses, with a two-sided P value, compared data from
continuous variables (e.g. age at diagnosis and maximum tumor diam-
eter) from subgroups of patients with and without AIP mutations. Sex
distribution and the proportions of patients with microadenomas and
macroadenomas in theAIPmutation-positive and negative groupswere
analyzed using the Fisher’s exact test, with a two-sided P value. A P
value of 0.05 was considered significant for all analyses.
AIP genetic analysis
Genomic DNA was isolated from blood samples from at least one
affected member of each FIPA family. The structure of AIP was based
on Ensembl sequences ENST00000279146, ENSG00000110711, and
ENSP00000279146. The primers used for the analysis of the AIP exonic
and flanking intronic sequences are as reported by Vierimaa et al. (12).
Each 25 l PCR reaction contained 150 ng genomic DNA, 1 m each
primer, 1.5 mmMgCl2, 10 mm Tris-HCl buffer (pH 8.3), 200 m dNTPs,
and 1.25 U FastStart Taq polymerase (Roche, Vilvoorde, Belgium). PCR
conditions were 95 C for 10 min, followed by 30 cycles of 30 sec at 95
C, 30 sec at 68 C, and 20 sec at 72 C. PCR products were sequenced using
ABI3100 and BigDye Terminator v3.1 technology (Applied Biosystems,
Foster City, CA). A total of 100 blood samples from non-FIPA subjects
in Belgium and Francewere analyzed to assess for polymorphisms in the
AIP sequence.
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Accession numbers
Theaccessionnumbers inGenBank for thenovelAIPmutations reported
in this study are: EF066502 (R271W), EF066503 (E174frameshift), EF066504
(delG47-R54), EF066505 (K241E), EF066506 (Q142X), EF066507 (Q217X),
EF066508 (Q239X), EF066509 (Q285frameshift), and EF066510 (R16H).
Results
Genetic screening
Atotal of 156 subjectswere identified among73 familieswith
the FIPA phenotype (see supplemental Table 1, published on
The Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org).Elevenof73 (15.1%)FIPAfamilieswere
found to have 10 different germline mutations in the AIP gene
(Fig. 1). Of these, nine AIP mutations in 10 families have not
been reported to date. The characteristics of FIPA families that
had AIP mutations are detailed in Table 1. There were three
novel mutations that led to premature stop codons: Q142X
(c.424CT), Q217X (c.649CT), and Q239X (c.715CT). In ad-
dition, one three-member family that had a previously de-
scribed R304X mutation (12) was identified (c.910CT).
Three missense mutations, R16H (c.47GA), R271W
(c.811CT), and K241E (c.721AG), were identified in four
FIPA families; R271W was found in two two-member fam-
ilies (Table 1). One two-member family had an in-frame
G47_R54del (c.138_161del24) mutation. A frameshift deletion,
E174frameshift (c.517_521delGAAGA), that led to a stop codon
after 21 incorrect amino acids was identified in a family with
three affected members. A second frameshift mutation in a
two-member family, Q285frameshift (c.854_857delAGGC),
was followed by a stop codon after 17 incorrect amino acids.
Characteristics of FIPA cohort
Demographic details and the phenotypic patterns of tu-
mors seen are outlined in Tables 2 and 3, respectively. Briefly,
families were divided equally (n  78 each) among homo-
geneous and heterogeneous FIPA patterns; two-member ho-
mogeneous prolactinoma (n  18) and somatotropinoma
(n  14) families were the most frequent. All but one het-
erogeneous FIPA family had at least one member with a
prolactinoma or a somatotropinoma. Mean age at diagnosis
was significantly lower in subjects with AIP mutations (n 
26 subjects) as compared with those without AIP mutations
(n 130 subjects) (25.7 11.3 vs. 38.8 16.8 yr, respectively;
P  0.0006). Mean maximum tumor diameter was signifi-
cantly larger in the group with AIP mutations (24.6  10.7
mm) than those without (14.5  10.1 mm; P  0.0005). Al-
though the proportion of patients with macroadenomas was
higher in the AIP mutation-positive group (88.5%) as com-
pared with the AIP mutation-negative group (71.2%), this
difference did not reach statistical significance.
AIP mutation screening in FIPA families
Family members of subjects with pituitary adenomas
and AIPmutations were contacted whenever possible and
underwent genetic screening. Subjects that were positive
for an AIP mutation were offered clinical assessment and
hormonal screening. A total of 45 apparently unaffected
relatives were screened, and nine individuals (mean age
39.7 yr; range 16–71) from five different families were
found to be positive for mutations in AIP. These asymp-
tomatic subjects did not have signs or symptoms sugges-
tive of pituitary tumors, while hormonal and radiological
screening was unremarkable.
Discussion
This study involving an extensive cohort of 73 families hav-
ing the FIPA phenotype has identified a total of 11 families
having 10 mutations in the AIP gene; nine of these mutations
were previously undescribed. The current study extends our
R16H
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Q239X
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FIG. 1. Representation of AIP protein sequence with the position of gene mutations noted in the FIPA cohort and other studies indicated. The
FKBP-PPI domain (amino acids 29–121) is shown in gray, and the three TPR domains (amino acids 189–296) are in light blue. The final
carboxy-terminal amino acids that are necessary for interactions of AIP with hsp90 and AhR are shown in orange.
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understanding of the type of tumors associated with AIP mu-
tations in the familial setting and increases the number of
known AIP mutations associated with FIPA from three to 12.
The clinical characteristics of this larger FIPA cohort are in line
with our previous data indicating a relative predominance of
prolactinomasandsomatotropinomas inFIPA,andanearlyage
at diagnosis, particularly in subjects with somatotropinomas
(13). Furthermore, in this studywe note that tumors in patients
with AIPmutations have a significantly larger mean diameter
than those in AIP mutation-negative patients, which could re-
flect amore aggressive disease profile. In the study byVierimaa
et al. (12) the pituitary tumors seen in families with AIPmuta-
tions were somatotropinomas or mixed GH/prolactin-secret-
ing tumors. We found that while the majority of FIPA families
withAIPmutations had somatotropinomas ormixedGH/pro-
lactin-secreting tumors, one family included a subject with a
nonsecreting tumor. This nonsecreting tumorwas immunohis-
tochemically negative for both GH and prolactin, and occurred
in conjunction with a prolactinoma in the other affected family
member. Hormonal patterns at diagnosis in “somatotropi-
noma” subjects with AIP mutations in FIPA families showed
that 13 hadGHhypersecretion, and eight had elevatedGHand
prolactin. The three subjects with prolactinomas had only hy-
perprolactinemia at diagnosis, while the subject with the non-
secreting tumor had hypopituitarism. An identical mutation
(R271W) was associated with somatotropinomas in two adults
in one family, and with a somatotropinoma (prolactin immu-
nohistochemistry negative) and a macroprolactinoma (in a 10-
yr-old child) in another family. Some heterogeneity in immu-
nohistochemical patterns was also evident, with tumors from
seven somatotropinoma patients having GH positivity only,
four showing GH and prolactin staining, and one stained for
GH and FSH.
Vierimaa et al. (12)undertookanextensiveanddetailedstudy
of multiple genes to assess linkage to pituitary adenomas oc-
curring in a familial setting, finally identifying AIP as being
associated with pituitary adenomas in large, well-described
kindreds in Finland. In that study an AIP mutation was iden-
tified in one family from Italy, but two other families with IFS
fromGermanyandTurkeyhadnormalAIP sequences (12).Our
TABLE 2. Demographic description of the FIPA cohort and the subgroup having AIP mutations
AIP mutation
positive
AIP mutation
negative P value
No. of families 11 62
No. of subjects 26 130
Sex
Males, n (%) 15 (57.7) 57 (43.8) NS
Females, n (%) 11 (42.3) 73 (56.2) NS
Median age (yr) at diagnosis (mean  SD) 24.5 (25.7  11.3) 36.0 (38.8  16.8) 0.0006
Median maximum tumor diameter (mm) (mean  SD) 24.0 (24.6  10.7) 10.0 (14.5  10.1)a 0.0005
Macroadenomas, n (%) 23 (88.5) 89 (71.2)a NS
NS, Clinically nonsecreting adenoma.
a Tumor size classification was not present for five individuals in the AIP mutation negative group.
TABLE 1. Disease characteristics in 11 FIPA families having AIP mutations
AIP mutation
No. of
affected
members
Relation
between
members
Disease type
Age at
diagnosis
(yr)
Tumor
characteristics
Preoperative
hormonal profile Immunohistochemistry
R16H 2 a. First cousin Acromegaly 46 Micro aGH, aPRL Not operated
b. First cousin Acromegaly N/A Micro aGH/IGF-I Not operated
G47_R54del 2 a. Brother Acromegaly 28 Macro, invasive aGH/IGF-I N/A
b. Brother Acromegaly 25 Macro, invasive aGH/IGF-I N/A
Q142X 4 a. Brother Gigantism 17 Macro aGH N/A
b. Brother Acromegaly 29 Macro aGH GH
c. Sister Acromegaly 17 Macro aGH N/A
d. Daughter of b. Prolactinoma N/A Micro aPRL Not operated
E174fs 3 a. Brother Acromegaly 17 Macro, invasive aGH/IGF-I/aPRL GH/PRL
b. Sister Acromegaly 25 Macro, invasive aPRL/slight aIGF-I Not operated
c. Aunt Acromegaly 35 Macro, invasive aGH/IGF-I/aPRL Not operated
Q217X 2 a. Brother Acromegaly 29 Macro, invasive aGH/IGF-I, aPRL GH, PRL
b. Sister Acromegaly 24 Macro aGH/IGF-I, aPRL GH
Q239X 2 a. Father Gigantism 14 Macro aGH N/A
b. Son Gigantism 15 Macro aGH/IGF-I GH
K241E 2 a. Brother Prolactinoma 40 Macro, invasive aPRL PRL
b. Sister Nonsecreting 53 Macro, invasive Hypopituitarism LH/SU
R271W 2 a. Father Acromegaly 42 Macro aGH N/A
b. Son Acromegaly 29 Macro aGH/IGF-I GH
R271W 2 a. Mother Acromegaly 22 Macro aGH GH, PRL
b. Son Prolactinoma 10 Macro aPRL N/A
Q285fs 2 a. Brother Acromegaly 32 Macro, invasive aGH/IGF-I, aPRL GH, FSH
b. Brother Gigantism 20 Macro, invasive aGH GH, PRL
R304X 3 a. Sister Acromegaly 19 Macro, invasive aGH/IGF-I, aPRL GH
b. Sister Acromegaly 21 Macro, invasive aGH/IGF-I GH/PRL
c. Nephew of a. Incipient
gigantism
9 Macro aGH/IGF-I Not operated
N/A, Not applicable; PRL, prolactin; SU, -subunit.
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data from screening a large, diverse population indicate that
AIPmutationsoccur inabout15%of families in theFIPAcohort.
The majority of FIPA families had normal germline AIP se-
quences, even those with three or four affected subjects. In
particular, of the 16 FIPA families with homogeneous presen-
tation of acromegaly (IFS), half were negative for AIP muta-
tions, indicating that this gene does not readily explain IFS in
its entirety. Other, as yet unidentified, genetic mutations may
be involved in producing the FIPA clinical phenotype. The
evidence to date suggests that mutations in AIPmay be linked
to the expression of a variety of tumor types. Although soma-
totropinomas predominate among FIPA families withAIPmu-
tations, both pure GH and mixed GH-prolactin secretion and
immunohistochemical staining occur commonly, even within
the same family. Heterogeneous expression of tumors in FIPA
tumor, includingprolactinomasor nonsecreting adenomas, can
occur in association with AIPmutations. The FIPA cohort con-
tained few patients with less common pituitary tumors such as
Cushing’s disease and only one patient with a TSH-secreting
adenoma; these were negative for AIPmutations. Therefore, it
remains to be seen whether AIP mutations can also occur in
families with Cushing’s disease or TSH-secreting adenomas.
A Q14X mutation was the one most frequently seen in the
Finnish patients studied, and both familial and sporadic
cases were associated with this germline mutation; tumor
analysis indicated loss of heterozygosity at theAIP locus (12).
One othermutation, IVS3–1GA,was reported in a sporadic
case of acromegaly. In the current study these mutations
were not identified in our international series of FIPA fam-
ilies. This, alliedwith the recent report of the absence of these
mutations in sporadic pituitary tumor patients treated in the
United States, suggests that these mutations may be char-
acteristic of the Finnish population (14). This would not be
unusual in terms of clinical genetics because Finland is
known to be relatively genetically homogeneous and subject
to founder effects (15). The role of extensive genealogic anal-
ysis such as that undertaken by Vierimaa et al. (12) to identify
distant links among various affected families is important.
We describe an Italian FIPA family with an R304X mutation
(c.910CT), the same mutation reported in an apparently
unrelated family elsewhere in Italy (12). Further studies may
highlight whether specific patterns of AIP mutations occur
among specific geographical or cultural groups.
The impact of reported mutations in AIP on protein ex-
pression and function remains to be determined. Data on the
structural components of AIP from in vitro studies provide
some indicators in that regard. AIP is a protein of 330 amino
acids in length, and contains conserved domains that include
three tetratricopeptide repeat (TPR) domains and a FK506
binding protein-type peptidyl-prolyl cis-trans isomerase
(FKBP-PPI) domain that is analogous to a related domain
found in immunophilin proteins. Although the function of
the FKBP-PPI domain remains to be determined fully, the
importance of the “carboxy half” of AIP (residues 154–330)
has been well established (16). Mutation studies of the third
TPRdomain have revealed that it is necessary for interactions
with both heat shock protein 90 (hsp90) and the aryl hydro-
carbon receptor (AhR) (17). Point mutations of the third TPR
domain in murine AIP, including Y268A, G272D, G272E,
A284T, and F288A, lead to an AIP that cannot coimmuno-
precipitate hsp90; of these, Y268A and G272D cannot coim-
munoprecipitate AhR (18). A further mutation, K266A, also
abrogated hsp90 binding but retained AhR binding, albeit at
a decreased level (19). Other studies that removed the last 32
amino acids from theC-terminal of AIP also prevented hsp90
binding, while the removal of the last 17 amino acids at the
C-terminal led to rapid AIP turnover within COS-1 cells (20).
Alanine replacement of any of the final four amino acids or
TABLE 3. Tumor types in homogeneous and heterogeneous FIPA families overall and in the subgroup of families with AIP mutations
Tumor type
Affected
members
per family
No. of
families in
FIPA cohort
No. of
affected subjects
in FIPA cohort
No. of
families with
AIP mutations
No. of
affected subjects
with AIP mutations
Homogeneous FIPA families
Prolactinoma 2 18 36 0 0
Somatotropinoma 2 14 28 6 12
3 2 6 2 6
Cushing’s disease 2 2 4 0 0
NS-adenoma 2 1 2 0 0
Gonadotropinoma 2 1 2 0 0
Homogeneous FIPA total 38 78 8 18
Heterogeneous FIPA families
Prolactinoma-somatotropinoma 2 8 16 1 2
4 1 4 1 4
Prolactinoma-NS-adenoma 2 8 16 1 2
3 1 3 0 0
Somatotropinoma-NS-adenoma 2 6 12 0 0
Prolactinoma-somatotropinoma-NS-adenoma 3 2 6 0 0
Prolactinoma-gonadotropinoma 2 3 6 0 0
Somatotropinoma-prolactinoma-Cushing’s disease 4 1 4 0 0
Somatotropinoma-prolactinoma-gonadotropinoma 3 1 3 0 0
Somatotropinoma-gonadotropinoma 2 1 2 0 0
Somatotropinoma-thyrotropinoma 2 1 2 0 0
Prolactinoma-Cushing’s disease 2 1 2 0 0
NS-adenoma-Cushing’s disease 2 1 2 0 0
Heterogeneous FIPA total 35 78 3 8
NS, Clinically nonsecreting adenoma.
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deletion of the final five amino acids at the C terminus of AIP
prevents AhR binding (19).
In families with mutations that led directly to stop codons
(Q142X, Q217X, Q239X, and R304X), the mutated gene would
not encode the third TPR domain, the carboxy terminal amino
acids, or both correctly (see supplemental Fig. 1, published on
The Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org). Two other frameshift mutations
(Q285fs and E174fs) also led to premature stop codons 17 and
21 amino acids downstream, respectively, and the loss of the
sequences coding for the hsp90 and AhR interaction sites on
AIP. TheG47_R54delmutation,which read in-frame thereafter,
would be expected to delete a series of amino acids within the
FKBP-PPI domain, which could interfere with the enzymatic
function of this region. In FIPA families with missense muta-
tions of AIP, the functional impact is somewhat more difficult
to predict. R271W, K241E, and R16H were not found in 100
non-FIPA individuals screened for AIP polymorphisms. Two
unrelated FIPA families had an R271W mutation in AIP. This
arginine is highly conserved across species, including the
mouse, and forms part of the critical third TPR domain. As
noted previously, mutation studies in this region in the mouse
are known to abrogate hsp90 or AhR binding, or both (17).
Given the sequence identity between the human being and
mouse in this important region, it appears reasonable to suggest
that R271W could interfere with the interaction of AIP and
hsp90/AhR in these subjects. BothK241 andR16 are conserved
amino acids across a variety of species; however, the impact of
such mutations on the structural and functional status of AIP
remains to be determined.
In conclusion, the current study shows thatAIPmutations
occur in 15% of families with the FIPA phenotype. AIP mu-
tations that may abrogate expression or function of AIP pro-
tein could impact subsequent AhR responses to cellular and
environmental signals, although AIP modulates a variety of
other cellular signals (e.g. phosphodiesterases, cAMP) that
may be involved in tumorigenesis. Experimental studies to
assess AIP protein expression, receptor interactions, and xe-
nobiotic responses will be useful in determining the precise
effect on pituitary tumorigenesis of the multiple AIP muta-
tions now identified.
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